— 01 · At a Glance
The centre in one paragraph.
★ Our practice in summary
The TPPL nuclear medicine practice operates as the Department of Nuclear Medicine within Fortis Memorial Research Institute, Sector 44, Gurugram — a JCI-accredited 1,000-bed quaternary-care hospital and ICPO-designated Clinical Theranostics Center of Excellence (2025). The department is the first centre in India to administer Lu-PSMA radioligand therapy, the only centre offering myeloablative I-131 MIBG therapy for high-risk paediatric neuroblastoma, and among the first to offer targeted alpha therapy with Ac-225. Every cycle is planned with our proprietary dosimetry algorithm and reviewed at the weekly multidisciplinary tumour board.
The page below covers the diagnostic and therapeutic infrastructure available to patients at this centre, the credentials of the clinical team, and the dedicated pathways we operate for international and national patients. For specific therapy protocols, please see the individual treatments pages; for the team, see our physicians.
Centre overview
The nuclear medicine floor at FMRI.
[Image: Wide-angle photograph of the nuclear medicine department reception — clean modern architecture, branded signage, ideally with a discreet patient or staff member in view to convey scale]
— 02 · ICPO Designation
An internationally designated Center of Excellence.
In 2025, our practice at Fortis Memorial Research Institute was granted designation as an ICPO Clinical Theranostics Center of Excellence by the International Centers for Precision Oncology (ICPO) Foundation — one of the global authorities on theranostic standards. The designation recognises centres that meet ICPO's published requirements and specifications for clinical theranostic delivery.
Aegroti salus suprema lex
ICPO
ICPO Clinical Theranostics Center of Excellence · 2025
Designated for endocrine neoplasia & prostate cancer.
The designation is granted specifically for two therapy categories where our centre's clinical experience and quality standards meet the ICPO benchmark for excellence:
Endocrine Neoplasia
Prostate Cancer
The certification is signed by two of the most internationally recognised figures in the global theranostics community:
Prof. Richard P. Baum
President, ICPO Academy for Theranostics
Chairman, ICPO Scientific Advisory Board
Prof. Rodney Hicks
Chairman, ICPO Centers Steering Committee
Certification visual
[Image: ICPO Clinical Theranostics Center of Excellence Certification 2025 — full certificate document with FMRI Gurugram designation, ICPO logo, and signatures of Prof. Richard P. Baum and Prof. Rodney Hicks]
For international patients, the ICPO designation is a meaningful trust signal — ICPO is a globally recognised foundation founded by leaders in the theranostics field, and its Centers Network includes a small group of clinical sites worldwide. The designation is reviewed and renewed periodically against updated ICPO standards.
— 03 · Clinical Firsts
What sets this centre apart.
Most nuclear medicine departments in India offer routine PET imaging and radioiodine therapy. A small handful add Lu-PSMA and PRRT. Our centre is one of the very few that delivers the full-spectrum radioligand therapy portfolio — including emerging alpha protocols — under one accredited roof, with the patient-safety standards that international quaternary care demands.
☆
First in India · Lutetium PSMA therapy
Our centre was the first in the country to initiate Lu-177 PSMA radioligand therapy for metastatic castration-resistant prostate cancer — before international approval of Pluvicto in 2022. Cumulative experience now exceeds many hundreds of cycles. Read the Lu-PSMA protocol →
☆
Only centre · Myeloablative MIBG for paediatric neuroblastoma
Our centre is currently the only centre in India offering myeloablative I-131 MIBG therapy for high-risk relapsed paediatric neuroblastoma — in collaboration with paediatric oncology and the radiation safety team. Read the MIBG protocol →
☆
Among the first · Targeted alpha therapy
Among the first centres in India to offer Ac-225 targeted alpha therapy for neuroendocrine tumours, metastatic prostate cancer, and select brain tumours — on a multidisciplinary-tumour-board-reviewed basis. Read the Alpha PSMA protocol → · Read the Alpha PRRT protocol →
☆
Primary referral centre · Radioiodine for thyroid cancer
The department is the primary regional referral centre for I-131 radioiodine ablation therapy in differentiated thyroid carcinoma — including high-dose protocols, dosimetry-guided dosing, and shielded inpatient administration.
— 04 · The Diagnostic Engine
Siemens Healthineers Biograph Vision.
Diagnostic imaging at our centre is anchored by the Siemens Healthineers Biograph Vision — a digital PET-CT system that succeeded our earlier Philips Time-of-Flight platform. The Biograph Vision is recognised as one of the most advanced clinical PET-CT systems globally, defining the standard of care for precision oncology imaging.
Siemens Biograph Vision
The world's fastest time-of-flight digital PET-CT.
[Image: Siemens Biograph Vision scanner in our scan room — full machine view, ideally lit to show the gantry, bore, and patient table; suite signage visible]
Across four practical measures, the Biograph Vision substantially exceeds conventional analog PET-CT systems still in routine use across most Indian centres:
- 2 to 3 millimetre lesion detection — unmatched sensitivity and resolution localise tumour foci that conventional PET-CT systems (typically 4 to 5 mm threshold) miss entirely. Critical for early staging, restaging, and recurrence detection.
- 50 percent radiation dose reduction — per scan, with preserved or improved image quality. Significant for paediatric, young-adult, and recurrent-imaging patients.
- World's fastest time of flight — FlowMotion seamless continuous scanning reduces whole-body acquisition time by approximately 30 to 50 percent. The patient lies in the scanner shorter, with less risk of motion artefact.
- 24 percent larger bore size — substantially improves comfort for claustrophobic patients and accommodates larger body sizes that older bores cannot. Reduces patient movement and improves image quality as a consequence.
Case in point · 63yo prostate cancer patient
A 2 mm focus that changed everything.
A 63-year-old gentleman with a history of carcinoma prostate was undergoing surveillance after primary treatment. Conventional PET-CT scans had shown no evidence of disease recurrence. On the Biograph Vision, however, the digital PET-CT revealed a tiny focus of intense PSMA uptake in the prostatic bed — precisely localising the site of relapse.
That single 2-millimetre finding changed his management from surveillance to active treatment — potentially before the recurrence had any chance to spread further. This is the diagnostic difference advanced imaging can make.
— 05 · PET Tracer Portfolio
The full PET tracer portfolio.
Beyond conventional F-18 FDG (which works for most cancers but not all), our centre offers the full Ga-68 ligand portfolio — specialist tracers that target specific receptors expressed by specific tumour types. These are the same tracers that determine eligibility for our radioligand therapy programmes.
18F · FDG
Most solid tumours · infection · inflammation
Fluorine-18 fluorodeoxyglucose — the standard PET tracer for most adult cancers. Detects metabolically active disease across lung, breast, lymphoma, colorectal, head & neck, and many others.
68Ga · DOTANOC
Neuroendocrine tumours · APUDOMAs
Gallium-68 DOTANOC — binds somatostatin receptors (SSTR-2) expressed on NETs. Used for diagnosis, staging, and eligibility assessment for PRRT and Alpha PRRT.
68Ga · PSMA
Prostate cancer staging & recurrence
Gallium-68 PSMA — the gold-standard imaging for prostate cancer. Detects PSMA-expressing prostate cancer cells at extremely low PSA levels. Determines eligibility for Lu-PSMA and Alpha PSMA therapy.
68Ga · Exendin
Insulinomas · Nesidioblastosis
Gallium-68 Exendin — a specialist tracer targeting GLP-1 receptors on pancreatic beta cells. Localises insulinomas (often very small, missed by anatomical imaging) and nesidioblastosis foci.
In addition, the centre is one of the few in the region to offer 4D PET-CT for radiation treatment planning and PET-CT-guided biopsies and interventional procedures — both of which require the diagnostic precision the Biograph Vision provides.
— 06 · Therapy Suite
The shielded radioligand therapy suite.
Radioligand and radioiodine therapy delivery requires specialised infrastructure that most hospitals don't have: a lead-shielded patient room, dedicated radiation-safe waste management, trained nursing staff, continuous dose-rate monitoring, and an AERB-licensed facility. Our centre has all of the above.
ι
Shielded inpatient suite
[Image: Inpatient isolation room interior — patient bed, intercom, glass viewing panel, AERB signage]
∞
Therapy infusion bay
[Image: Outpatient infusion suite — reclined chair, IV pole, monitoring equipment]
The therapy unit routinely administers the complete radioligand and radioisotope therapy portfolio. Several of these are not routinely available at most Indian centres:
131I
Radioiodine ablation · thyroid cancer
Primary referral
177Lu
Lu-PSMA · metastatic prostate cancer
First in India
131I
Only centre · myeloablative
90Y
TARE · liver cancer & liver NET mets
Routine
The shielded inpatient suite is licensed for high-dose protocols including myeloablative MIBG, high-dose radioiodine, and prolonged-stay alpha therapy regimens. Discharge criteria follow AERB dose-rate thresholds (typically < 30 μSv/h at 1 m), measured daily.
— 07 · Proprietary Dosimetry
A proprietary dosimetry algorithm.
Radioligand therapy is fundamentally a radiation dose delivered to a patient's tumour. The therapeutic effect, the side effect profile, and the inter-cycle decision-making all depend on accurately measuring how much radiation is actually reaching the disease — and how much is reaching healthy organs that need to be protected.
Our centre uses an in-house proprietary dosimetry algorithm for every radioligand therapy cycle, applied to three sequential clinical tasks:
- Radioligand uptake assessment — quantifying how much of the targeting molecule (Lu-PSMA, Lu-DOTATATE, Ac-225 PSMA, Ac-225 DOTATATE, mIBG) actually binds the patient's tumour, validating eligibility and predicting response.
- Patient-specific dose assessment — calculating the radiation dose received by the tumour and by dose-limiting organs (kidneys, marrow, salivary glands) at a per-patient level, rather than the one-size-fits-all default doses used at most centres.
- Inter-cycle monitoring — tracking how uptake and dose distribution change between cycles. If the tumour stops taking up the radioligand effectively, the algorithm flags it and the team escalates to an alternative (alpha line, FAPI, mIBG, or systemic).
Patient-specific dosimetry is recommended in international consensus guidelines but is not routinely performed at most Indian centres because of the computational and clinical workflow burden. Our algorithm encodes our team's collective experience across many hundreds of radioligand cycles — effectively converting that experience into reproducible patient-by-patient dosing decisions.
— 08 · Multidisciplinary Tumour Board
Weekly tumour board review.
Every complex theranostic case at our centre is reviewed at the weekly multidisciplinary tumour board at FMRI. The tumour board brings together the multiple specialists whose perspectives are needed to plan and adjust radioligand therapy in a patient's wider treatment journey.
- Nuclear medicine — Dr. Ishita B. Sen, Dr. Dharmender Malik and the radioligand therapy team
- Medical and surgical oncology — for cancer-treatment integration, prior chemotherapy sequencing, and systemic therapy compatibility
- Urology — for prostate cancer patients (Lu-PSMA / Alpha PSMA candidates)
- Endocrinology — for NET patients on somatostatin analogs and patients with thyroid, adrenal, or pancreatic primary disease
- Radiation oncology — for radiation-planning coordination and re-irradiation considerations
- Paediatric oncology — for paediatric neuroblastoma MIBG candidates
- Diagnostic radiology and pathology — for imaging and tissue interpretation
For international patients, the weekly tumour board meets before treatment commences, with the referring physician invited to join by video where they wish. The post-board treatment plan is formalised in writing and shared with the patient.
— 09 · Gamma Camera & SPECT
The Brightview X gamma camera.
Alongside PET-CT, the department operates a Philips Brightview X dual-head gamma camera — one of the most versatile dual-head systems in the industry, with a wide range of detector movements and acquisition protocols supporting both routine SPECT studies and specialist procedures.
SPECT capability
Philips Brightview X · dual-head gamma camera.
[Image: Brightview X gamma camera in scan room — both detector heads visible, patient table, control workstation in background]
The department performs the full routine nuclear medicine portfolio:
- Bone scans — metastasis screening, fracture detection, infection
- Renal scans — DTPA, DMSA, GFR assessment
- Stress myocardial perfusion scans — coronary artery disease assessment
- Parathyroid scans — pre-operative localisation
- Brain SPECT — perfusion, dementia work-up, epilepsy
- Ventilation-perfusion (V/Q) scans — pulmonary embolism
- Venography and lymphangiography — vascular and lymphatic studies
Plus several sophisticated studies not routinely offered at most centres in the region:
- In-vitro plasma GFR assessment — gold-standard renal function measurement, particularly important before PRRT and chemotherapy regimens that demand precise dosing
- Labelled leucocyte scans — for occult infection localisation
- Trodat (TRODAT-1) imaging — dopamine transporter imaging for Parkinson's disease and parkinsonian syndromes
- Radioiodine uptake studies — with our dedicated radioiodine probe
— 10 · International Patients
For international patients.
We operate a dedicated concierge programme for international patients seeking nuclear medicine and theranostic care at our centre. Most of our international patients reach us via referral from urologists, oncologists, or endocrinologists abroad — or directly after researching specific radioligand therapy options.
Before you travel
Pre-arrival support.
Imaging & record review by Dr. Ishita B. Sen — submit your PET, CT, MRI, biochemistry and treatment summary; written clinical opinion returned within 72 hours
Second Read of your PET, CT, MRI or pathology — independent re-read with 72-hour turnaround
Indicative treatment plan and cost confirmation in writing
Hospital invitation letter on FMRI letterhead for your medical visa application
Medical visa documentation — medical e-visa typically issued in 72–96 hours; paper medical visa typically issued in 5–7 working days
When you arrive
On-arrival concierge.
Airport transfer — coordinator meets you at IGI Delhi (30 km / 30–60 min from FMRI)
Accommodation coordination — partner hotels and serviced apartments within 5–15 min of FMRI
International Lounge access at FMRI — a dedicated private waiting and rest area reserved for international patients
Dedicated in-hospital coordinator — single point of contact for the duration of treatment, exclusively for international patients of the Nuclear Medicine department
Interpreter support — Arabic, Russian, French, Bengali, and several African languages
Discharge documentation in English plus translated summary if requested
For countries where the medical-e-visa process is slower or more nuanced, our coordinators provide additional supporting documentation including detailed treatment timeline, costs in USD or EUR, and direct communication with consular offices on request. WhatsApp our international team for a personalised plan.
— 11 · National Patients
For national patients.
For patients within India, our centre operates as the regional referral hub for specialist nuclear medicine. Most national patients reach us via referral from a medical oncologist, urologist, endocrinologist, or paediatric oncologist. Direct enquiries are also welcomed.
First contact
Three entry routes.
Online consultation — 20-minute Google Meet with Dr. Ishita B. Sen, suitable for second-opinion-level review or pre-treatment planning
Second Read service — independent re-read of an existing PET, CT, or MRI by Dr. Sen with formal written report. INR 2,500. 72-hour turnaround
In-person consultation at FMRI Sector 44 with appointment
During treatment
What to expect.
Day-care infusion for most outpatient radioligand therapies (Lu-PSMA, PRRT, Alpha PSMA, Alpha PRRT)
Inpatient isolation for high-dose I-131 and MIBG protocols — typically 3–5 nights
Weekly multidisciplinary tumour board at FMRI for complex cases requiring oncology / urology / endocrinology coordination
Insurance pre-authorisation pack prepared by our coordinators for major Indian insurers
Inter-cycle remote follow-up by WhatsApp / email between scheduled visits
— 12 · The Hospital
About Fortis Memorial Research Institute.
FMRI is one of the flagship quaternary-care hospitals of the Fortis Healthcare network and one of the most internationally-recognised hospitals in north India. The campus accommodates more than 1,000 beds across multiple specialty centres including oncology, cardiology, neurosciences, orthopaedics, transplant, and paediatrics — alongside the nuclear medicine and theranostics department we operate.
For the nuclear medicine patient, the practical advantage of being embedded within FMRI rather than a standalone centre is cross-specialty backup. When a radioligand therapy patient develops a cardiac issue, the cardiology team is in the same building. When a paediatric MIBG patient needs intensive supportive care, paediatric ICU is in the same hospital. When an international patient's underlying surgical question needs a urology review, the urologist is on-campus.
- JCI accreditation — gold-standard global accreditation for patient safety and care quality, recognised by international insurers
- NABH accreditation — the equivalent national-level Indian accreditation
- 1,000+ beds across multi-specialty care, with full ICU and CCU support
- Weekly multidisciplinary tumour boards — involving oncology, urology, endocrinology, radiation oncology and our nuclear medicine team for complex case review
- 24/7 emergency, blood bank, and pharmacy
For a complete overview of FMRI as an institution, see the FMRI hospital page.
— 13 · Location
Getting to FMRI.
FMRI · Sector 44
[Image: Embedded Google Maps view — FMRI Sector 44 with surrounding landmarks visible]
Address
Sector 44, Opposite HUDA City Centre Metro Station,
Gurugram, Haryana 122002 · India
From IGI Airport, Delhi
Approximately 30 km · 30–60 minutes by car. Concierge transfer arranged for international patients.
By Metro
HUDA City Centre station (Yellow Line) is directly opposite the hospital — 2 min walk.
Frequently asked questions.
Fortis Memorial Research Institute (FMRI) is located in Sector 44, Gurugram, Haryana, opposite HUDA City Centre Metro Station. The hospital is approximately 30 km from Indira Gandhi International Airport (IGI), Delhi — typically 30 to 60 minutes by car depending on traffic.
FMRI is one of the flagship multi-specialty quaternary-care hospitals of the Fortis Healthcare network.
Yes. Fortis Memorial Research Institute is accredited by Joint Commission International (JCI) — the gold standard for healthcare quality and patient safety, recognised globally. JCI accreditation requires the hospital to meet several hundred international patient-safety and care-quality standards, audited on-site every three years.
FMRI also holds NABH (National Accreditation Board for Hospitals and Healthcare Providers) accreditation in India.
Yes. Fortis Memorial Research Institute, Gurugram is a designated ICPO Clinical Theranostics Center of Excellence (2025) for endocrine neoplasia and prostate cancer.
The designation is granted by the International Centers for Precision Oncology (ICPO) Foundation — the global authority on theranostic standards — and is signed by Prof. Richard P. Baum (President, ICPO Academy for Theranostics; Chairman, ICPO Scientific Advisory Board) and Prof. Rodney Hicks (Chairman, ICPO Centers Steering Committee). Both are internationally renowned figures in the global theranostics community.
The designation places FMRI within a small group of centres worldwide that meet the ICPO requirements and specifications for clinical theranostic delivery.
Yes. FMRI welcomes international patients from across the world and operates a dedicated international patient services desk. Our Theranostic Physicians nuclear medicine practice has an additional concierge programme for international cancer patients — covering airport transfer, accommodation coordination, medical visa documentation, online pre-treatment consultation, and language-supported in-hospital coordination.
Patients commonly travel to us from the Middle East, Africa, Southeast Asia, Central Asia, North America and Europe.
Most foreign nationals require a medical visa to receive treatment in India. Two routes are available, with different processing times:
Medical e-visa — typically issued in 72 to 96 hours of online application. Paper medical visa — typically issued in 5 to 7 working days. Both are valid for 60 days with multiple-entry options.
To support your application, our coordinators provide a hospital invitation letter on FMRI letterhead, a treatment plan from Dr. Ishita B. Sen, and indicative cost confirmation. We email the documentation pack within 48 hours of consultation. Specific requirements vary by country — our team confirms the current rules for your nationality at the consultation.
A PET-CT scan combines two imaging techniques in a single examination. Positron Emission Tomography (PET) uses a small dose of a radioactive tracer that highlights areas of abnormal metabolic activity (commonly cancer, infection or inflammation). Computed Tomography (CT) provides a detailed anatomical map. Combined, the two locate where in the body the abnormal metabolic activity is occurring.
The most common PET tracer is F-18 FDG (used for many cancers); specialty tracers include Ga-68 PSMA for prostate cancer, Ga-68 DOTANOC for neuroendocrine tumours, and Ga-68 Exendin for insulinomas.
The Siemens Healthineers Biograph Vision is a digital PET-CT that significantly outperforms conventional analog PET-CT systems in three measurable ways:
Lesion detection sensitivity — Biograph Vision routinely detects 2 to 3 millimetre lesions versus 4 to 5 millimetre on conventional systems. Scan speed — total whole-body scan time is reduced by roughly 30 to 50 percent through the world's fastest time-of-flight technology. Radiation dose — the system uses approximately 50 percent less radiation per scan while preserving or improving image quality.
The 24 percent larger bore size also improves patient comfort, particularly for claustrophobic or larger patients.
India has several internationally recognised cancer centres — including Tata Memorial Hospital (Mumbai), AIIMS Delhi, Fortis Memorial Research Institute (Gurgaon), Apollo (multiple cities), Medanta and Max Healthcare. The most appropriate hospital depends on your specific cancer type, stage, and the required treatment modality.
For nuclear medicine and theranostic radioligand therapies (Lu-PSMA, PRRT, MIBG, targeted alpha therapy), FMRI's nuclear medicine department is recognised as one of the leading centres in India — pioneering Lu-PSMA therapy in the country, the only centre offering myeloablative MIBG for high-risk paediatric neuroblastoma, and one of the first to offer targeted alpha therapy.
The TPPL nuclear medicine department at FMRI Gurgaon includes:
Siemens Healthineers Biograph Vision digital PET-CT; Philips Brightview X dual-head gamma camera with SPECT capability; dedicated radioiodine uptake probe; and shielded inpatient therapy suite compliant with Atomic Energy Regulatory Board (AERB) standards.
The department routinely performs the full PET tracer portfolio (F-18 FDG, Ga-68 DOTANOC, Ga-68 PSMA, Ga-68 Exendin), 4D PET-CT for radiation planning, PET-CT-guided biopsy, all routine and sophisticated SPECT studies, and the complete radioligand therapy portfolio — radioiodine, Lu-177 PSMA, Lu-177 DOTATATE, Ac-225 PSMA, Ac-225 DOTATATE, I-131 MIBG, Tb-161, and TARE.
FMRI is approximately 30 kilometres from Indira Gandhi International Airport (IGI). Typical travel time by car is 30 to 60 minutes depending on traffic — usually faster in the early morning or late evening, slower during weekday business hours.
International patients enrolled in our concierge programme are met at the airport by a coordinator, with pre-arranged transfer directly to the hospital or to their accommodation. The HUDA City Centre metro station is directly opposite the hospital for patients using public transport.
FMRI has interpreter and translation support across multiple languages including Arabic, Russian, French, Bengali, and several African languages. All consultations with Dr. Ishita B. Sen and the clinical team are conducted in English, with on-call interpreter support available for any consultation, ward round, or imaging procedure.
Translated treatment summaries and discharge documentation can be provided on request. The international patient services desk operates seven days a week.
IS
[Image: Dr. Sen portrait]
Written & Medically Reviewed By
Dr. Ishita B. Sen
MBBS · DRM · DNB (Nuclear Medicine) · 30+ years in nuclear oncology
Director and Head, Department of Nuclear Medicine and Molecular Imaging, Fortis Memorial Research Institute. Visiting fellowships at Memorial Sloan Kettering Cancer Center, New York and University of Marburg, Germany. Past President, Association of Nuclear Medicine Physicians of India. Pioneer of Lu-PSMA therapy in India.
FellowshipsMSK New York · Marburg
Past PresidentANMPI
SpecialtyFull-spectrum theranostic radioligand therapy
Full profile